An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors

(2019) Kyung Hwan Kim et al.   CLINICAL CANCER RESEARCH

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

(2019) Derek L. Clouthier et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches

(2019) Aaron J Franke et al.   JNCI-Journal of the National Cancer Institute

Reprogramming the Epigenome With Vitamin C

(2019) Taylor Lee Chong et al.   Frontiers in Cell and Developmental Biology

Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies

(2018) Michael R. Savona et al.   AMERICAN JOURNAL OF HEMATOLOGY

Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

(2018) Ganjun Yu et al.   Cellular & Molecular Immunology

Phase I Study of CC-486 Alone and in Combination With Carboplatin or nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors

(2018) Daniel D. Von Hoff et al.   CLINICAL CANCER RESEARCH

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

(2018) Hope S. Rugo et al.   CLINICAL CANCER RESEARCH

OUP accepted manuscript

(2018)   HUMAN MOLECULAR GENETICS

The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy

(2018) Helen Loo Yau et al.   TRENDS IN CELL BIOLOGY

Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells

(2018) Christian Gerecke et al.   Oncotarget

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028

(2018) Andrea Varga et al.   GYNECOLOGIC ONCOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats

(2017) David Brocks et al.   NATURE GENETICS

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

(2017) Meredith L. Stone et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

(2017) Nilofer S. Azad et al.   Oncotarget

Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi

(2016) Jean-Philippe Fortin et al.   BIOINFORMATICS

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment

(2016) Stefani Spranger   INTERNATIONAL IMMUNOLOGY

Near-optimal probabilistic RNA-seq quantification

(2016) Nicolas L Bray et al.   NATURE BIOTECHNOLOGY

Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine

(2016) Minmin Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

(2015) Jean-Pierre J Issa et al.   LANCET ONCOLOGY

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

(2015) C. R. Cogle et al.   ONCOLOGIST

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model

(2015) L. Wang et al.   Cancer Immunology Research

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

(2015) Huili Li et al.   Oncotarget

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies

(2014) A O Gang et al.   Blood Cancer Journal

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

(2014) Charity W Law et al.   GENOME BIOLOGY

Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10

(2013) Christoph Burkart et al.   EMBO Molecular Medicine

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

(2009) M Koopman et al.   BRITISH JOURNAL OF CANCER

Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology

(2008) T. Pal et al.   CLINICAL CANCER RESEARCH

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH